Cargando…

Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia

Obinutuzumab is used for the treatment of chronic lymphocytic leukemia. So far there are no data of using this for retreatment in patients who have received it previously. We introduced obinutuzumab for the retreatment in a chronic lymphocytic leukemia patient, who had first achieved partial remissi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khurana, Sharad, Ahmed, Salman, Alegria, Victoria R, Aulakh, Sonikpreet, Ailawadhi, Meghna, Singh, Anshika, Chanan-Khan, Asher, Ailawadhi, Sikander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350017/ https://www.ncbi.nlm.nih.gov/pubmed/30728976 http://dx.doi.org/10.1177/2050313X18823917

Ejemplares similares

Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia
por: Kumar, Vivek, et al.
Publicado: (2019)

Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting
por: Jayakrishnan, Thejus, et al.
Publicado: (2021)

Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review
por: Parrondo, Ricardo D., et al.
Publicado: (2020)

RETRACTED ARTICLE: Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy
por: Longcor, Jarrod, et al.
Publicado: (2022)

Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature
por: Baksh, Mizba, et al.
Publicado: (2021)

The digital divide: Racial disparities in adoption and utilization of health information technology among patients with lymphoid cancers
por: Ailawadhi, Sikander, et al.
Publicado: (2023)

Myelomatous ascites and pleural effusion in relapsed multiple myeloma
por: Baksh, Mizba, et al.
Publicado: (2022)

Second primary acute lymphoblastic leukemia in adults: a SEER analysis of incidence and outcomes
por: Swaika, Abhisek, et al.
Publicado: (2017)

A Panel Evaluation of the Changes in the General Public’s Social-Media-Following of United States’ Public Health Departments during COVID-19 Pandemic
por: Khokhar, Areej, et al.
Publicado: (2021)

Immunophenotyping of Waldenströms Macroglobulinemia Cell Lines Reveals Distinct Patterns of Surface Antigen Expression: Potential Biological and Therapeutic Implications
por: Paulus, Aneel, et al.
Publicado: (2015)

Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia
por: Seiter, Karen, et al.
Publicado: (2015)

Clinical application of obinutuzumab for treating chronic lymphocytic leukemia
por: Luan, Chunyan, et al.
Publicado: (2019)

New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab
por: Shah, Arpita
Publicado: (2015)

Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab
por: Smolej, Lukáš
Publicado: (2014)

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy
por: Al-Sawaf, Othman, et al.
Publicado: (2017)

Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
por: Hampel, Paul J., et al.
Publicado: (2022)

Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia
por: Hill, Brian T, et al.
Publicado: (2015)

Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia
por: Cerquozzi, Sonia, et al.
Publicado: (2015)

Obinutuzumab in a patient with chronic lymphocytic leukemia-associated paraneoplastic pemphigus
por: Freund, Johanna, et al.
Publicado: (2022)

Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups
por: Ailawadhi, S, et al.
Publicado: (2014)

Successful Retreatment With Venetoclax in a Patient With Chronic Lymphocytic Leukemia
por: Jackson, Ross A., et al.
Publicado: (2022)

Obinutuzumab‐induced serum sickness following salvage therapy for chronic lymphocytic leukemia
por: Saba, Julie, et al.
Publicado: (2017)

Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma
por: Ailawadhi, Sikander, et al.
Publicado: (2018)

Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia
por: Evans, Sarah S., et al.
Publicado: (2015)

Obinutuzumab: A FDA approved monoclonal antibody in the treatment of untreated chronic lymphocytic leukemia
por: Sachdeva, Mamta, et al.
Publicado: (2015)

Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies
por: Kittai, Adam S., et al.
Publicado: (2021)

Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia
por: Samuels, Courtney, et al.
Publicado: (2021)

Posterior Reversible Encephalopathy Syndrome Triggered by Obinutuzumab in a Patient with Chronic Lymphocytic Leukemia
por: Atef, Bentolhoda, et al.
Publicado: (2023)

Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics
por: Razavi, P, et al.
Publicado: (2013)

Targeted treatment for chronic lymphocytic leukemia
por: Masood, Aisha, et al.
Publicado: (2011)

Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: A systematic review and meta-analysis
por: Aulakh, Sonikpreet, et al.
Publicado: (2020)

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab
por: Jain, Punit, et al.
Publicado: (2016)

Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study
por: Fresa, Alberto, et al.
Publicado: (2022)

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial
por: Moreno, Carol, et al.
Publicado: (2022)

Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain
por: Casado, Luis Felipe, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_f4o39gkrj72f0c0t0acovs7ncn